肠道转运时间对柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）偶氮还原的影响。
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
作者信息
van Hees P A, Tuinte J H, van Rossum J M, van Tongeren J H
出版信息
Gut. 1979 Apr;20(4):300-4. doi: 10.1136/gut.20.4.300.
Abstract
During a normal and an accelerated intestinal transit, in seven healthy volunteers, the recoveries of salicylazosulphapyridine (SASP) and its split products sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA) were determined in urine and faeces. The azo-reduction of SASP and consequently the recovery of 5-ASA in the faeces was found to be substantially decreased during an accelerated intestinal transit. In addition, in 18 patients with inflammatory disease of the colon during maintenance therapy of SASP it could be demonstrated that the serum SP levels were related to the diarrhoeal state and did not correlate with disease activity. As recent studies have reported that 5-ASA is possibly the active therapeutic moiety of SASP, the ineffectiveness of SASP therapy in patients with active colitis may be ascribed to the reduced azo reduction of SASP as the result of profuse diarrhoea.
摘要
在七名健康志愿者的正常和加速肠道转运过程中，测定了尿和粪便中柳氮磺胺吡啶（SASP）及其分解产物磺胺吡啶（SP）和5-氨基水杨酸（5-ASA）的回收率。发现在加速肠道转运过程中，SASP的偶氮还原以及粪便中5-ASA的回收率显著降低。此外，在18例接受SASP维持治疗的结肠炎症性疾病患者中，可以证明血清SP水平与腹泻状态相关，与疾病活动度无关。由于最近的研究报道5-ASA可能是SASP的活性治疗部分，因此SASP治疗对活动性结肠炎患者无效可能归因于腹泻过多导致SASP的偶氮还原减少。
相似文献
1
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).肠道转运时间对柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）偶氮还原的影响。
Gut. 1979 Apr;20(4):300-4. doi: 10.1136/gut.20.4.300.
2
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Scand J Gastroenterol. 1986 Aug;21(6):693-700. doi: 10.3109/00365528609011102.
3
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.柳氮磺胺吡啶、其代谢产物及其他5-氨基水杨酸前体药物的临床药代动力学。
Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001.
4
5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
Eur J Clin Pharmacol. 1986;31(1):23-6. doi: 10.1007/BF00870980.
5
Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.柳氮磺胺吡啶、5-氨基水杨酸和磺胺吡啶对兔结肠黏膜中前列腺素合成及代谢的影响。
Prostaglandins. 1985 Jan;29(1):133-42. doi: 10.1016/0090-6980(85)90158-3.
6
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）在人体中的处置与代谢。
Br J Clin Pharmacol. 1982 Apr;13(4):523-8. doi: 10.1111/j.1365-2125.1982.tb01415.x.
7
Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.
Res Commun Chem Pathol Pharmacol. 1975 Nov;12(3):571-81.
8
Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.
Pharm Res. 1989 Dec;6(12):1067-72. doi: 10.1023/a:1015938706685.
9
5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.含5-氨基水杨酸的药物。人体中的递送、转归及可能的临床意义。
Dan Med Bull. 2000 Feb;47(1):20-41.
10
Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
J Pharmacol Exp Ther. 1976 Jul;198(1):240-5.
引用本文的文献
1
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.改善溃疡性结肠炎中氨基水杨酸盐的给药方式：对患者预后的影响。
Drugs. 2008;68(8):1089-103. doi: 10.2165/00003495-200868080-00006.
2
Comparative tolerability of therapies for ulcerative colitis.溃疡性结肠炎治疗方法的耐受性比较
Drug Saf. 2002;25(8):561-82. doi: 10.2165/00002018-200225080-00003.
3
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.多次口服齐留通对柳氮磺胺吡啶及其代谢产物磺胺吡啶和N - 乙酰磺胺吡啶稳态药代动力学的影响。
Clin Pharmacokinet. 1995;29 Suppl 2:98-104. doi: 10.2165/00003088-199500292-00014.
4
Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.两种新型柳氮磺胺吡啶类似物——依沙拉嗪和巴柳氮的研究。
Dig Dis Sci. 1983 Jul;28(7):609-15. doi: 10.1007/BF01299921.
5
Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927.
6
Sulphasalazine and male infertility: reversibility and possible mechanism.柳氮磺胺吡啶与男性不育：可逆性及可能机制
Gut. 1981 Jun;22(6):445-51. doi: 10.1136/gut.22.6.445.
7
Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.柳氮磺胺吡啶对活动期克罗恩病患者的疗效：一项对照双盲研究。
Gut. 1981 May;22(5):404-9. doi: 10.1136/gut.22.5.404.
8
9
Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.缺血性心脏病、克罗恩病及抗菌治疗对磺吡酮药代动力学的影响。
Clin Pharmacokinet. 1986 Sep-Oct;11(5):402-10. doi: 10.2165/00003088-198611050-00005.
10
Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.在正常和加速肠道转运时间内，5-氨基水杨酸从颇得斯安（Pentasa）中的释放情况。
Br J Clin Pharmacol. 1987 Mar;23(3):365-9. doi: 10.1111/j.1365-2125.1987.tb03061.x.
本文引用的文献
1
PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.泼尼松作为溃疡性结肠炎缓解期的维持治疗药物。
Lancet. 1965 Jan 23;1(7378):188-9. doi: 10.1016/s0140-6736(65)90973-6.
2
CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.柳氮磺胺吡啶治疗溃疡性结肠炎的对照试验
Gut. 1964 Oct;5(5):437-42. doi: 10.1136/gut.5.5.437.
3
Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.柳氮磺胺吡啶和水杨酸偶氮磺胺嘧啶治疗溃疡性结肠炎
Lancet. 1962 May 26;1(7239):1094-6. doi: 10.1016/s0140-6736(62)92080-9.
4
Distribution studies of salicylazosulfapyridine and its metabolites.柳氮磺胺吡啶及其代谢产物的分布研究。
Gastroenterology. 1973 Feb;64(2):240-5.
5
Absorption, metabolism, and excretion of salicylazosulfapyridine in man.柳氮磺胺吡啶在人体中的吸收、代谢及排泄
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51. doi: 10.1002/cpt1972134539.
6
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）对溃疡性结肠炎进行长期维持治疗的对照治疗试验。
Gut. 1973 Dec;14(12):923-6. doi: 10.1136/gut.14.12.923.
7
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢。I. 住院患者中代谢产物与治疗反应的关系
Gut. 1973 Aug;14(8):631-41. doi: 10.1136/gut.14.8.631.
8
Determination of salicylazosulphapyridine in biological materials.
Acta Pharm Suec. 1973 May;10(2):107-10.
9
Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.柳氮磺胺吡啶给药后生物材料中磺胺吡啶及其代谢产物的测定
Acta Pharm Suec. 1973 Mar;10(1):87-92.
10
Active therapeutic moiety of sulphasalazine.
Lancet. 1978 Feb 4;1(8058):277. doi: 10.1016/s0140-6736(78)90524-x.
Zotero 插件